J9395 Injection, fulvestrantInjection, fulvestrant, 25 mg
J9395 payment limit: $5.021 per 25 MG, effective October 1, 2026 through December 31, 2026, based on 2Q26 ASP data. Coinsurance 20%.
00310-0720-10 Faslodex, AstraZeneca Pharmaceuticals LP: 20 billing units per package (2 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS)16729-0436-30 Fulvestrant, Accord Healthcare Inc: 20 billing units per package (2 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS)62332-0650-10 Fulvestrant, Alembic Pharmaceuticals Inc.: 20 billing units per package (2 SYRINGE in 1 CARTON / 5 mL in 1 SYRINGE)70121-1463-02 Fulvestrant, Amneal Pharmaceuticals, LLC: 20 billing units per package (2 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS)70860-0211-74 Fulvestrant, Athenex Pharmaceutical Division, LLC: 20 billing units per package (2 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS)83634-0203-74 Fulvestrant, Avenacy Inc.: 20 billing units per package (2 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS)68001-0484-85 Fulvestrant, BluePoint Laboratories: 20 billing units per package (2 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS)68001-0522-85 Fulvestrant, BluePoint Laboratories: 20 billing units per package (2 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS)68001-0626-85 Fulvestrant, BluePoint Laboratories: 20 billing units per package (2 SYRINGE in 1 CARTON / 5 mL in 1 SYRINGE)43598-0262-02 Fulvestrant, Dr. Reddy's Laboratories Inc.: 20 billing units per package43598-0262-23 Fulvestrant, Dr. Reddy's Laboratories Inc.: 20 billing units per package (2 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS)55150-0394-02 Fulvestrant, Eugia US LLC: 20 billing units per package (2 SYRINGE in 1 CARTON / 5 mL in 1 SYRINGE)63323-0715-05 Fulvestrant, FreseniUS Kabi USA, LLC: 20 billing units per package (2 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS)00143-9022-02 Fulvestrant, Hikma Pharmaceuticals USA Inc.: 20 billing units per package (2 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS)71288-0555-86 Fulvestrant, Meitheal Pharmaceuticals Inc.: 20 billing units per package (2 SYRINGE in 1 CARTON / 5 mL in 1 SYRINGE)16714-0070-02 Fulvestrant, Northstar RxLLC: 20 billing units per package (2 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS)25021-0462-74 Fulvestrant, Sagent Pharmaceuticals: 20 billing units per package25021-0471-74 Fulvestrant, Sagent Pharmaceuticals: 20 billing units per package (2 SYRINGE in 1 CARTON / 5 mL in 1 SYRINGE)00781-3532-12 Fulvestrant, Sandoz Inc.: 20 billing units per package (2 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS)00781-9055-12 Fulvestrant, Sandoz Inc.: 20 billing units per package (2 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS)70700-0284-98 Fulvestrant, Xiromed, LLC: 20 billing units per package (2 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS)70710-1688-08 Fulvestrant, Zydus Pharmaceuticals (USA) Inc.: 20 billing units per package (2 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS)Status E: excluded from the PFS by regulation.
32 of 38 payer prior-auth lists that name J9395 require prior authorization or set conditions: Blue Cross Blue Shield of Arizona (AZ Blue), CarePlus Health Plans, Cigna, HealthSpring, Humana, Molina Healthcare of California, Molina Healthcare of Illinois, UnitedHealthcare, UnitedHealthcare Community Plan.
J9395 appears in 21 coverage policies from Aetna, BlueCross BlueShield of South Carolina, Centene, Premera Blue Cross.
| Payer | Policy | Role in policy | Reviewed | Document |
|---|---|---|---|---|
| Aetna | Hematopoietic Cell Transplantation for Hodgkin's Disease (0495) | listed, no stance (range J9000-J9999) | Jul 2, 2026 | payer document |
| Aetna | Hematopoietic Cell Transplantation for Multiple Myeloma (0497) | listed, no stance (range J9000-J9999) | Aug 5, 2026 | payer document |
| Aetna | Hematopoietic Cell Transplantation for Selected Childhood Solid Tumors (0496) | listed, no stance (range J9000-J9999) | Aug 6, 2026 | payer document |
| Aetna | Hematopoietic Cell Transplantation for Thalassemia Major and Sickle Cell Anemia (0626) | listed, no stance (range J9000-J9999) | Sep 18, 2026 | payer document |
| Aetna | Infusion Pumps (0161) | covered if criteria are met (range J9000-J9999) | Mar 31, 2026 | payer document |
| Aetna | Injectable Medications (0020) | listed, no stance (range J9000-J9999) | Mar 5, 2026 | payer document |
| Aetna | Margetuximab-cmkb (Margenza) (0985) | listed, no stance (range J9000-J9999) | May 27, 2026 | payer document |
| Aetna | Negative Pressure Wound Therapy (0334) | listed, no stance (range J9000-J9999) | Jun 8, 2026 | payer document |
| Aetna | Pertuzumab Products (0973) | listed, no stance (range J9000-J9999) | Apr 27, 2026 | payer document |
| Aetna | Pharmacogenetic and Pharmacodynamic Testing (0715) | listed, no stance | Oct 8, 2026 | payer document |
| Aetna | Phototherapy and Photochemotherapy (PUVA) for Skin Conditions (0205) | listed, no stance (range J9000-J9999) | May 18, 2026 | payer document |
| Aetna | Revakinagene Taroretcel-lwey (Encelto) (1079) | listed, no stance (range J8501-J9999) | Oct 5, 2026 | payer document |
| Aetna | Sacituzumab Govitecan-hziy (Trodelvy) (0971) | listed, no stance | Apr 24, 2026 | payer document |
| Aetna | Trastuzumab Products (0313) | listed, no stance | Jun 8, 2026 | payer document |
| Aetna | Tumor Chemoresistance Assays (0758) | listed, no stance (range J9000-J9999) | Dec 2, 2025 | payer document |
| Aetna | Tumor Chemosensitivity Assays (0245) | listed, no stance (range J9000-J9999) | Apr 13, 2026 | payer document |
| BlueCross BlueShield of South Carolina | Hematopoietic Cell Transplantation for Breast Cancer (CAM 80127) | listed, no stance (range J9000-J9999) | Jul 1, 2026 | payer document |
| BlueCross BlueShield of South Carolina | Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults (CAM 80124) | unproven / investigational (range J9000-J9999) | Jul 1, 2026 | payer document |
| BlueCross BlueShield of South Carolina | Hematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome (CAM 80117) | listed, no stance (range J9000-J9999) | Jan 1, 2026 | payer document |
| Centene | Fulvestrant (Faslodex Injection) (CP.PHAR.424) | covered if criteria are met | Aug 1, 2026 | payer document |
| Premera Blue Cross | Selective Estrogen Receptor Modulators and Down Regulators (5.01.618) | listed, no stance | Jun 22, 2026 | payer document |
Prior authorization required or conditional in VA.
From payers' published prior-auth lists, coverage policies and state Medicaid fee schedules, updated Oct 16, 2026. The role is what the policy's own code table or text says about the code. Not a guarantee of coverage or payment; verify with the payer. CPT® is a registered trademark of the American Medical Association.